Drug Interaction Study of CT1812 in Healthy Volunteers
Status:
Completed
Trial end date:
2017-02-15
Target enrollment:
Participant gender:
Summary
This is Phase 1, single-center, open-label, single-sequence drug-drug interaction study to
determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs
(tolbutamide, midazolam, dextromethorphan and omeprazole).